BR0112086A - Anticorpos para mcp-1 humano - Google Patents

Anticorpos para mcp-1 humano

Info

Publication number
BR0112086A
BR0112086A BR0112086-7A BR0112086A BR0112086A BR 0112086 A BR0112086 A BR 0112086A BR 0112086 A BR0112086 A BR 0112086A BR 0112086 A BR0112086 A BR 0112086A
Authority
BR
Brazil
Prior art keywords
antibodies
mcp
human mcp
human
eotaxin
Prior art date
Application number
BR0112086-7A
Other languages
English (en)
Inventor
Peter Hiestand
Hans Hofstetter
Trevor Glyn Payne
Roman Urfer
Franco Di Padova
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0112086A publication Critical patent/BR0112086A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"ANTICORPOS PARA MCP-1 HUMANO". A presente invenção refere-se a moléculas de ligação de MCP-1 compreendendo pelo menos um domínio variável de cadeia pesada de imunoglobulina (V~ H~) compreendendo as regiões hipervariáveis CDR1, CDR2 e CDR3 de seq³ência tal como definido, para emprego no tratamento de distúrbios ou doenças mediadas por MCP-1 ou eotaxina.
BR0112086-7A 2000-06-30 2001-06-29 Anticorpos para mcp-1 humano BR0112086A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0016138.0A GB0016138D0 (en) 2000-06-30 2000-06-30 Organic compounds
PCT/EP2001/007468 WO2002002640A2 (en) 2000-06-30 2001-06-29 Antibodies to human mcp-1

Publications (1)

Publication Number Publication Date
BR0112086A true BR0112086A (pt) 2003-05-06

Family

ID=9894801

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112086-7A BR0112086A (pt) 2000-06-30 2001-06-29 Anticorpos para mcp-1 humano

Country Status (27)

Country Link
US (1) US20040047860A1 (pt)
EP (1) EP1299421B1 (pt)
JP (2) JP3920215B2 (pt)
KR (1) KR100603899B1 (pt)
CN (1) CN100486996C (pt)
AR (1) AR046379A1 (pt)
AT (1) ATE426616T1 (pt)
AU (2) AU2001283903B2 (pt)
BR (1) BR0112086A (pt)
CA (1) CA2412775A1 (pt)
CZ (1) CZ20024256A3 (pt)
DE (1) DE60138102D1 (pt)
EC (1) ECSP024402A (pt)
ES (1) ES2322643T3 (pt)
GB (1) GB0016138D0 (pt)
HU (1) HUP0301477A3 (pt)
IL (1) IL153721A0 (pt)
MX (1) MXPA03000201A (pt)
NO (1) NO20026063L (pt)
NZ (1) NZ523195A (pt)
PE (1) PE20020125A1 (pt)
PL (1) PL207133B1 (pt)
PT (1) PT1299421E (pt)
RU (1) RU2314316C2 (pt)
SK (1) SK18122002A3 (pt)
WO (1) WO2002002640A2 (pt)
ZA (1) ZA200300199B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU778392B2 (en) 2000-03-03 2004-12-02 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
EP2990394A1 (en) 2001-11-30 2016-03-02 Biogen MA Inc. Antibodies against monocyte chemotactic proteins
RS20050834A (en) 2002-08-19 2007-12-31 Abgenix Inc., Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
AU2003262051B2 (en) * 2002-09-12 2008-09-25 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman MCP-1 antibody and antibody fragment thereof
US20050232923A1 (en) * 2003-11-05 2005-10-20 Li Yan Methods and compositions for treating MCP-1 related pathologies
WO2005108431A1 (en) * 2004-05-04 2005-11-17 University Of Kentucky Research Foundation Methods and compositions for the treatment of ocular neovascularization
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
TW200716174A (en) * 2005-05-19 2007-05-01 Centocor Inc Anti-MCP-1 antibodies, compositions, methods and uses
US8114964B2 (en) 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
WO2007147026A2 (en) * 2006-06-15 2007-12-21 Centocor, Inc. Ccr2 antagonists for chronic organ transplantation rejection
CA2658719A1 (en) * 2006-07-24 2008-01-31 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
MX2009003762A (es) * 2006-10-05 2009-07-10 Centocor Ortho Biotech Inc Antagonistas del receptor cc-quimiocina 2 para el tratamiento de fibrosis.
AU2007337983A1 (en) 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (CCL2, CCL3, CCL5, CXCL11, CXCL12) single-domain antibodies
CA2692392A1 (en) * 2007-06-29 2009-01-08 Centocor Ortho Biotech Inc. Anti- mcp-1 antibodies, compositions, methods and uses
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
BRPI0916973A2 (pt) 2008-08-18 2016-07-26 Amgen Fremont Inc anticorpos para ccr2
EP2328930B1 (en) 2008-08-20 2014-12-24 Probiodrug AG Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe)
EP3409792B1 (en) * 2009-06-25 2023-09-20 Fred Hutchinson Cancer Center Method of measuring adaptive immunity
WO2013192596A2 (en) 2012-06-22 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind ccr2
EP3180026A4 (en) * 2014-08-15 2018-04-11 Pixarbio Corporation Compositions for inhibiting inflammation in a subject with a spinal cord injury and methods of using the same
CN104198727A (zh) * 2014-08-22 2014-12-10 广西南宁隆吉维特生物科技有限公司 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法
EP3050574B1 (en) 2015-01-28 2019-10-09 Universite De Bordeaux Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease
CN105695495B (zh) * 2015-12-07 2020-02-18 中国石油大学(华东) 一种高活性人趋化因子的制备方法及用途
WO2018106959A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CN108048408B (zh) * 2018-01-26 2020-02-07 扬州大学 牛单核细胞趋化蛋白-1杂交瘤细胞株、其分泌的单克隆抗体及应用
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
JPWO2020213665A1 (pt) 2019-04-17 2020-10-22
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP7415005B2 (ja) 2019-12-18 2024-01-16 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｃｌ２抗体
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
WO2006085961A2 (en) * 2004-06-30 2006-08-17 Centocor, Inc. Anti-mcp-1 antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
ECSP024402A (es) 2003-02-06
CA2412775A1 (en) 2002-01-10
ES2322643T3 (es) 2009-06-24
NZ523195A (en) 2005-09-30
HUP0301477A3 (en) 2005-11-28
ZA200300199B (en) 2003-11-13
JP2004502421A (ja) 2004-01-29
CN1443199A (zh) 2003-09-17
CZ20024256A3 (cs) 2003-04-16
KR100603899B1 (ko) 2006-07-25
KR20030014272A (ko) 2003-02-15
ATE426616T1 (de) 2009-04-15
MXPA03000201A (es) 2003-05-27
PT1299421E (pt) 2009-06-26
AU8390301A (en) 2002-01-14
AR046379A1 (es) 2005-12-07
CN100486996C (zh) 2009-05-13
IL153721A0 (en) 2003-07-06
PL207133B1 (pl) 2010-11-30
SK18122002A3 (sk) 2003-06-03
AU2001283903B2 (en) 2005-06-02
NO20026063L (no) 2003-02-27
JP2007054079A (ja) 2007-03-08
HUP0301477A2 (hu) 2003-08-28
NO20026063D0 (no) 2002-12-17
EP1299421B1 (en) 2009-03-25
PL359854A1 (en) 2004-09-06
EP1299421A2 (en) 2003-04-09
JP3920215B2 (ja) 2007-05-30
US20040047860A1 (en) 2004-03-11
RU2314316C2 (ru) 2008-01-10
GB0016138D0 (en) 2000-08-23
PE20020125A1 (es) 2002-03-12
DE60138102D1 (de) 2009-05-07
WO2002002640A2 (en) 2002-01-10
WO2002002640A3 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
BR0112086A (pt) Anticorpos para mcp-1 humano
TNSN06087A1 (en) Therapeutic binding molecules
CY1124289T1 (el) Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7
GEP20074222B (en) Antibodies to cd40
HRP20090527T1 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
AR035581A1 (es) Anticuerpos para il-1beta humana
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
WO2002072832A3 (en) Therapeutic binding molecules
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
NZ595235A (en) Compositions and methods for increasing muscle growth
SG151284A1 (en) Antibodies against ccr5 and uses thereof
CU23292B7 (es) Anticuerpos monoclonales humanos de ctla-4
TW200716182A (en) Antibodies directed to CD20 and uses thereof
SI2902039T1 (en) Antagonist antibodies to IL-17
EA200601752A1 (ru) Антимиостатиновые антитела
MXPA06003788A (es) Anticuerpos completamente humanos contra 4-1bb humano (cd137).
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
NZ596381A (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
TW200517124A (en) Fully human antibodies against human 4-1BB
BR0109549A (pt) Utilização de moléculas que se ligam a cd25 no tratamento de doenças inflamatórias do trato gastrointestinal
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος
TH53886A (th) แอนติบอดี้ต่อ il-1b ในมนุษย์
TH79793A (th) โมเลกุลของแอนติบอดีที่มีความจำเพาะต่อ il-17 ของมนุษย์
TH64455A (th) สารภูมิต้านทาน mcp-1 ในมนุษย์

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2232 DE 15/10/2013.